Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBT Margin: 2010-2024

Historic EBT Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to -3.62%.

  • Ani Pharmaceuticals' EBT Margin rose 3607.00% to 14.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.11%, marking a year-over-year increase of 746.00%. This contributed to the annual value of -3.62% for FY2024, which is 770.00% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported EBT Margin of -3.62% as of FY2024, which was down 188.57% from 4.08% recorded in FY2023.
  • Ani Pharmaceuticals' EBT Margin's 5-year high stood at 4.08% during FY2023, with a 5-year trough of -25.94% in FY2021.
  • Moreover, its 3-year median value for EBT Margin was -3.62% (2024), whereas its average is -6.45%.
  • As far as peak fluctuations go, Ani Pharmaceuticals' EBT Margin plummeted by 1,398bps in 2020, and later spiked by 2,389bps in 2023.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' EBT Margin stood at -12.45% in 2020, then crashed by 1,348bps to -25.94% in 2021, then skyrocketed by 613bps to -19.81% in 2022, then skyrocketed by 2,389bps to 4.08% in 2023, then plummeted by 770bps to -3.62% in 2024.